Skip to main content

Table 1 Patients’ characteristics at the inclusion

From: Clinical assessment and train-of-four measurements in critically ill patients treated with recommended doses of cisatracurium or atracurium for neuromuscular blockade: a prospective descriptive study

Characteristics

All patients

N = 119

Center 1 (cisatracurium use)

N = 97

Center 2 (atracurium use)

N = 22

Age (years)

62 (52–73)

62 (51–72)

63 (52–73)

Male [n (%)]

78 (66)

61 (63)

17 (77)

Body mass index (kg/m2)

25.5 (23.4–29.6)

25.3 (23.1–29.6)

26.6 (23.7–32.2)

SAPS II (points)

51 (40–62)

50 (40–62)

51 (44–60)

SOFA (points)

9 (6–12)

9 (7–12)

9 (6–12)

Length of stay before ICU (days)

1 (0–4)

1 (0–4)

1 (0–3)

Main reason for ICU admission [n (%)]

   

 Medical

111 (93)

93 (96)

18 (82)*

 Surgical

8 (7)

4 (4)

4 (18)

Main reason for neuromuscular blockade [n (%)]

 ARDS

94 (79)

78 (80)

16 (73)*

 Exacerbations of COPD

7 (6)

5 (5)

2 (9)

 Status asthmaticus

3 (3)

3 (3)

0

 Other respiratory failures

6 (5)

5 (5)

1 (4.5)

 Abdominal compartment syndromes

5 (4)

2 (2)

3 (13.5)

 Miscellaneous

4 (3)

4 (4)

0

Main comorbidities [n (%)]

 Diabetes

16 (13)

14 (14)

2 (9)

 Renal disease

8 (7)

7 (7)

1 (5)

 Cirrhosis

16 (13)

14 (14)

2 (9)

 Corticosteroid treatment

12 (10)

11 (11)

1 (5)

Sepsis [n (%)]

85 (71)

68 (70)

17 (77)

Catecholamines [n (%)]

78 (66)

62 (64)

16 (73)

Renal replacement therapy [n (%)]

9 (8)

6 (6)

3 (14)

  1. Continuous variables are reported as medians and interquartile ranges (25th–75th percentiles), and categorical variables as numbers and percentages
  2. SAPS II Simplified Acute Physiologic Score II, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, ARDS acute respiratory distress syndrome, COPD chronic obstructive pulmonary disease
  3. p < 0.05 center 1 versus center 2